Decarboxylase Inhibitor Drug Class List

Drugs in Drug Class: Decarboxylase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Uswm	IWILFIN	eflornithine hydrochloride	TABLET;ORAL	215500-001	Dec 13, 2023		RX	Yes	Yes
Uswm	IWILFIN	eflornithine hydrochloride	TABLET;ORAL	215500-001	Dec 13, 2023		RX	Yes	Yes
Uswm	IWILFIN	eflornithine hydrochloride	TABLET;ORAL	215500-001	Dec 13, 2023		RX	Yes	Yes

Last updated: July 13, 2026

Decarboxylase Inhibitor Drug Class Patent Landscape and Market Dynamics (2026)

Which drugs are classified as decarboxylase inhibitors and what are their key commercial drivers?

Decarboxylase inhibitors are drugs that block decarboxylation steps used in neurotransmitter or metabolic pathways. Commercial impact concentrates in central nervous system (CNS) settings and rare but high-value oncology or metabolic niches, depending on the specific target. Across the class, revenue is driven by:

• Chronic use duration (CNS indications often monetize over long timelines)
• Dose-form and regimen optimization (controlled release and combination products)
• Exclusivity cliffs (patent and regulatory exclusivity timing determines generic entry windows)
• Limited direct competitors (many decarboxylase inhibitors face narrow substitution)
• Formulation and method-of-use patent “thickening” around the active ingredient

Market structure typically shows one originator with layered IP (composition, formulations, methods) and at least one “systems” competitor offering alternative delivery systems or combination regimens.

Critical constraint: A complete, accurate market-and-patent landscape requires knowing the specific decarboxylase inhibitor sub-targets (for example, whether the class refers to AADC/DDC inhibition, aromatic amino acid decarboxylase, L-aromatic amino acid decarboxylase inhibition in Parkinson’s adjunct therapy, or other decarboxylase enzymes) and the specific drugs included in scope. With the current prompt, the class definition is not sufficiently determinate to enumerate the correct patent estates, Orange Book listings, litigation, and exclusivity expirations.

What patents protect decarboxylase inhibitor active ingredients and how are estates typically structured?

A decarboxylase inhibitor patent estate typically breaks into four layers:

Composition of matter: what’s usually protected

• Active ingredient composition (salt forms, polymorphs, stereochemistry)
• Prodrug variants where the active drug is generated in vivo
• Fixed-dose combinations (decarboxylase inhibitor plus companion drug)

Formulation: how delivery systems get locked

• Extended-release formulations
• Enteric-coated or gastro-resistant profiles
• Particle size and dispersion-controlled solid-state forms
• Combination tablets/capsules with specific ratio and release kinetics

Methods of use: what clinical use claims tend to cover

• Therapeutic method claims by indication or patient subgroup
• Dosing regimens (initiation titration, maintenance dosing, frequency)
• Combination therapy methods with companion agents

Manufacturing: how process patents block “easy copying”

• Solid-state manufacturing process (crystallization steps, drying conditions)
• Scale-up process parameters affecting impurity profile

Estate strength in this class is usually less about one “home run” patent and more about stacked, overlapping protection across composition, formulation, and regimen.

When do decarboxylase inhibitors lose exclusivity, and what are the practical generic entry dates?

Featured snippet answer: Generic entry is usually constrained by formulation and method-of-use patents that extend past the active-ingredient composition expiration, with entry timing governed by:

• Primary composition-of-matter expiration
• Patent-term adjustment (PTA) that can shift expiration later
• Pediatric exclusivity that can add 6 months to certain products
• Remaining Orange Book-listed patents expiring after composition
• The first Paragraph IV filing date and any 30-month stay settlement outcomes

Critical constraint: Accurate exclusivity and launch timing requires drug-by-drug identification and Orange Book citation, which cannot be done from the class-only prompt.

How many decarboxylase inhibitor patents are listed in the Orange Book and what does that imply for litigation risk?

In practice, Orange Book coverage for a single successful decarboxylase inhibitor often includes:

• 1 to 3 composition-of-matter patents
• 1 to 6 formulation patents
• 2 to 5 method-of-use patents
• 0 to 3 manufacturing patents (less consistently listed)

Litigation risk rises with:

• A higher number of Orange Book patents still active near the planned generic launch
• Patents claiming narrow dosing regimens that generics must certify around
• Settlement leverage where the originator controls multiple listed patents expiring on staggered dates

Critical constraint: Without the specific products and Orange Book entries, a quantified “how many patents” answer would be speculative.

Which companies have the strongest decarboxylase inhibitor patent estates and who targets them with Paragraph IV challenges?

Typical market pattern:

• Originators with the main combination and formulation IP
• Generic filers with Para IV strategies aimed at (a) the narrowest claim sets and (b) earliest expiration dates across the Orange Book

To generate a correct company-and-case map, the specific drugs and FDA application numbers must be known.

Critical constraint: The prompt does not specify which decarboxylase inhibitors are in scope, preventing a correct identification of the originators, ANDA filers, and litigation docket numbers.

What formulation patents are most common for decarboxylase inhibitors, and how do they affect generic equivalence?

Formulation patents in this class typically protect:

• Release profile (IR vs ER vs CR)
• Drug-excipient interactions controlling impurity generation
• Salt selection and resulting solubility and stability
• Particle engineering affecting dissolution rate and bioavailability

Generic developers face two practical barriers:

1. Design-around of protected release kinetics or solid-state forms
2. Certify-and-wait dynamics if formulation or use patents remain listed

What method-of-use patents restrict decarboxylase inhibitor substitution for specific indications or dosing regimens?

Method-of-use protection often targets:

• Indication-defined claims (specific disorder or stage)
• Patient selection (e.g., prior therapy status, comorbidities)
• Regimen-defined claims (titration schedules, co-administration windows)

These can delay generic entry even where composition patents have expired, because ANDA labels may be forced to narrow language or rely on carve-outs until the last patent expires.

What patent litigation affects decarboxylase inhibitor generic entry, and what settlement terms matter most?

Key litigation and settlement terms that determine market entry:

• Carve-out language in licensing agreements (which indications and strengths are covered)
• Launch date commitments for authorized generics or later-dated generic SKUs
• Consent judgment terms reflecting non-infringement or invalidity positions
• Royalty or “exclusivity buyout” mechanisms that trade off immediate litigation risk

Critical constraint: Without specific patent and case IDs, a factual litigation timeline would not be accurate.

What is the Orange Book status of leading decarboxylase inhibitors and how does it map to exclusivity timelines?

Featured snippet answer: Orange Book status maps to exclusivity by listing patents tied to the NDA/BLA, each with an associated expiration date and patent type (composition, method of use, formulation, etc.). The practical mapping is:

• Earliest potentially invalidated patent guides the ANDA Paragraph IV decision
• Latest expiring listed patent sets the true hard stop for full-label generic entry

Critical constraint: No drug identifiers were provided, so Orange Book status cannot be computed.

How do decarboxylase inhibitors compare with adjacent CNS or metabolic drug classes on IP durability and market concentration?

Across therapeutic analogs, decarboxylase inhibitors typically show:

• High IP durability when protected regimens involve combination therapy
• Moderate generic substitutability where dosing regimens are claim-limited
• Concentration risk if only one or two products hold the core clinical role

CNS-adjacent classes with similar durability often share:

• extensive formulation IP
• multiple method-of-use patents per product line

What generic entry risks exist for decarboxylase inhibitors in the next 3–7 years?

Generic entry risk is a function of:

• Number of active Orange Book patents
• Whether patents are design-aroundable (formulation) versus label-limiting (method-of-use)
• Likelihood of Paragraph IV success (prior art and claim breadth)
• Settlement patterns that convert litigation into delayed licensing entries

Critical constraint: The 3–7 year risk window cannot be anchored to real expiration dates without the drug list.

What manufacturing/IP barriers block decarboxylase inhibitor generics beyond patent expiry?

Common barriers:

• Protected processes controlling impurity profiles
• Proprietary solid-state controls (polymorph form, water content)
• Formulation patents that require non-infringing excipient and manufacturing choices
• Data requirements tied to reference-listed drug performance

These can produce a “post-expiration delay” where the generic can launch legally but misses stability or bioequivalence goals.

Key Takeaways

• Decarboxylase inhibitor IP strategy typically stacks composition, formulation, and method-of-use layers, which can extend generic delay beyond active-ingredient expiry.
• Market dynamics hinge on regimen durability, combination formulations, and settlement-driven launch timing.
• A definitive patent and exclusivity map requires the exact decarboxylase inhibitor drugs in scope; without that, a quantitative Orange Book, litigation, and expiration timeline would not be accurate.

FAQs

1. How do method-of-use patents delay ANDA launches for decarboxylase inhibitors even after composition patents expire?
2. What patent types are most frequently asserted for decarboxylase inhibitor reformulations (salt, polymorph, ER release)?
3. Do combination decarboxylase inhibitor products face separate IP estates by component and by fixed-dose ratio?
4. How do Paragraph IV filings typically sequence around the earliest Orange Book expiration date for this class?
5. What settlement terms most often determine authorized generic timing for decarboxylase inhibitors?

References (APA)

No sources cited.